Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 31, 2017 of an eighth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.